Rheumatology Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (Rx Drugs, OTC Drugs), By Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Regional Insights and Forecast to 2035

Rheumatology Therapeutics Market Overview

The global Rheumatology Therapeutics Market size estimated at USD 51274.42 million in 2026 and is projected to reach USD 65487 million by 2035, growing at a CAGR of 2.76% from 2026 to 2035.

The global Rheumatology Therapeutics Market is expanding as autoimmune and inflammatory disorders become more widely diagnosed and treated with targeted medicines. Rheumatoid arthritis affects about 0.5%–1% of adults globally, while osteoarthritis affects more than 500 million people worldwide. Biologic drugs, biosimilars, Janus kinase inhibitors, conventional disease-modifying antirheumatic drugs, and corticosteroids remain important treatment categories. North America and Europe account for a substantial portion of specialty rheumatology treatment demand, supported by established healthcare systems and high biologic adoption. 

In the USA, rheumatoid arthritis affects approximately 1.5 million adults, with women representing roughly 70% of diagnosed cases. Osteoarthritis affects more than 32 million U.S. adults, creating substantial demand for pain management and disease-modifying treatment approaches. The U.S. market is characterized by strong adoption of biologic therapies, targeted synthetic DMARDs, JAK inhibitors, corticosteroids, and biosimilars. More than 20 biosimilars for certain major biologic medicines have gained U.S. regulatory approval across therapeutic categories, increasing the relevance of cost-efficient treatment. 

Key Findings

• Key Market Driver: Approximately 70% of rheumatoid arthritis patients are women, while roughly 0.5%–1% of adults globally are affected, creating persistent demand for chronic immunomodulatory treatment and long-term rheumatology care.
• Major Market Restraint: Biologic therapies can represent substantially higher treatment costs than conventional DMARDs, while approximately 30%–50% of patients may experience adherence or persistence challenges with long-term chronic therapy.
• Emerging Trends: Biosimilars, targeted therapies, precision medicine, and oral treatment options are increasing their influence, with biosimilars potentially generating 15%–40% price reductions in selected biologic treatment categories.
• Regional Leadership: North America contributes approximately 35%–40% of global rheumatology therapeutics demand, while Europe represents around 25%–30%, reflecting comparatively high diagnosis, specialist access, biologic use, and reimbursement coverage.
• Competitive Landscape: Large pharmaceutical companies account for a significant proportion of advanced rheumatology treatment sales, while biologics, biosimilars, JAK inhibitors, and specialty medicines collectively represent a dominant share of competitive therapeutic activity.
• Market Segmentation: Rheumatoid arthritis represents approximately 25%–35% of major rheumatology treatment demand in many developed markets, while osteoarthritis, psoriatic arthritis, lupus, gout, and ankylosing spondylitis collectively contribute substantial shares.
• Recent Development: Biosimilar and targeted-treatment launches have increased competitive activity, with selected biosimilars achieving treatment-cost reductions of approximately 15%–40% compared with reference biologic therapies.

Rheumatology Therapeutics Market Latest Trends

The Rheumatology Therapeutics Market is increasingly shifting from broad immunosuppression toward targeted treatment strategies designed around disease pathways and individual patient characteristics. Biologic DMARDs, targeted synthetic DMARDs, interleukin inhibitors, tumor necrosis factor inhibitors, and JAK inhibitors remain important areas of pharmaceutical development. Biosimilars are also changing procurement strategies because selected products can reduce treatment costs by approximately 15%–40%, depending on therapy, market, payer structure, and competition. In rheumatoid arthritis, treatment-to-target approaches increasingly emphasize achieving remission or low disease activity rather than simply reducing symptoms. Digital patient monitoring, remote consultations, laboratory-based disease assessment, and medication-adherence technologies are also becoming more relevant to specialist care.

Another important Rheumatology Therapeutics Market Trend is the growing focus on earlier intervention and differentiated treatment selection. Approximately 0.5%–1% of adults worldwide have rheumatoid arthritis, creating a large long-term treatment population. Osteoarthritis, affecting more than 500 million people globally, is strengthening demand for nonsteroidal anti-inflammatory drugs, corticosteroid interventions, analgesics, and emerging disease-modifying approaches. Pharmaceutical companies are increasingly evaluating therapies for difficult-to-treat autoimmune conditions, including systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis, and vasculitis. The Rheumatology Therapeutics Market Forecast is therefore increasingly shaped by biosimilar competition, oral targeted medicines, personalized treatment, safety monitoring, improved diagnostics, and expanded specialty-care access.

Rheumatology Therapeutics Market Dynamics

DRIVER

"Growing Burden of Autoimmune and Inflammatory Diseases"

The primary Rheumatology Therapeutics Market driver is the large and persistent population affected by chronic autoimmune, inflammatory, and musculoskeletal disorders. Rheumatoid arthritis affects approximately 0.5%–1% of adults worldwide, while osteoarthritis affects more than 500 million people globally. In the USA, approximately 1.5 million adults have rheumatoid arthritis and more than 32 million have osteoarthritis. These conditions commonly require long-term management, creating recurring demand for DMARDs, biologics, targeted synthetic therapies, corticosteroids, analgesics, and anti-inflammatory medicines. 

RESTRAINTS

"High Cost and Safety Complexity of Advanced Therapies"

High treatment costs remain a major restraint for the Rheumatology Therapeutics Market, particularly for biologic medicines and advanced targeted therapies. Conventional DMARDs such as methotrexate are generally less expensive, whereas biologic and targeted therapies can involve substantially greater annual treatment expenditures. Cost differences can influence physician prescribing, payer authorization, patient adherence, and treatment switching. 

OPPORTUNITY

"Expansion of Biosimilars and Precision Rheumatology"

Major Rheumatology Therapeutics Market Opportunities are emerging through biosimilar adoption, precision medicine, personalized treatment, and expansion into underdiagnosed autoimmune diseases. Biosimilars can create meaningful savings in mature biologic categories, with selected products producing approximately 15%–40% lower treatment costs compared with reference medicines. This creates opportunities for manufacturers, contract development organizations, distributors, payers, and healthcare providers to expand patient access while controlling expenditure. 

CHALLENGE

"Complex Treatment Decisions and Unequal Patient Access"

A key Rheumatology Therapeutics Market Challenge is the complexity of selecting and maintaining appropriate treatment across heterogeneous autoimmune and inflammatory diseases. Patients can respond differently to the same biologic, conventional DMARD, or targeted synthetic therapy, requiring treatment switching or combination strategies. Some therapies require screening, laboratory monitoring, infection assessment, or ongoing safety surveillance, increasing healthcare-system workload. 

Rheumatology Therapeutics Market Segmentation

The Rheumatology Therapeutics Market is segmented by type and application according to treatment classification and distribution channel. By type, the market includes Rx Drugs and OTC Drugs, reflecting differences in prescription requirements, therapeutic intensity, clinical supervision, and patient use. By application, demand is distributed across Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy channels. Prescription medicines account for the larger portion of advanced rheumatology treatment utilization, while pharmacy channels increasingly support chronic disease management. Market segmentation is influenced by rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, lupus, treatment accessibility, medication adherence, reimbursement policies, and increasing demand for convenient medicine distribution.

BY TYPE

Rx Drugs: Prescription drugs represent the dominant therapeutic category in the Rheumatology Therapeutics Market because many moderate-to-severe inflammatory and autoimmune rheumatic diseases require physician-directed treatment and ongoing clinical monitoring. Rx Drugs include conventional disease-modifying antirheumatic drugs such as methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide, along with biologic DMARDs, targeted synthetic DMARDs, corticosteroids, and other prescription anti-inflammatory medicines. Rheumatoid arthritis affects approximately 0.5%–1% of adults worldwide, creating a substantial long-term prescription treatment population. In the United States, around 1.5 million adults are estimated to have rheumatoid arthritis, while more than 32 million adults have osteoarthritis. Prescription treatment is particularly important where disease progression can cause permanent joint damage, functional impairment, or systemic complications. 

OTC Drugs: Over-the-counter drugs form an important supportive segment of the Rheumatology Therapeutics Market, particularly for symptom management involving mild-to-moderate musculoskeletal pain, stiffness, inflammation, and discomfort. OTC products commonly include selected nonsteroidal anti-inflammatory drugs, topical analgesics, topical counterirritants, and other nonprescription pain-relief products, depending on national regulations. This category is especially relevant to osteoarthritis, which affects more than 500 million people worldwide and represents one of the largest sources of chronic musculoskeletal symptoms. OTC therapies can provide convenient short-term relief and are frequently used before or alongside specialist treatment. However, OTC products generally do not replace disease-modifying therapies for autoimmune conditions such as rheumatoid arthritis because they primarily address symptoms rather than underlying immune-mediated disease activity. 

BY APPLICATION

Hospital Pharmacy: Hospital pharmacies represent a critical application segment in the Rheumatology Therapeutics Market because they support diagnosis, initiation, monitoring, and management of patients with moderate-to-severe rheumatic and autoimmune diseases. Hospital pharmacy demand is particularly significant for prescription medicines requiring specialist supervision, infusion services, complex dosing, laboratory monitoring, or multidisciplinary care. Biologic therapies, injectable medicines, corticosteroids, immunomodulators, and other specialty products can require controlled storage, clinical verification, and medication reconciliation. Rheumatoid arthritis affects approximately 0.5%–1% of adults globally, while systemic lupus erythematosus, psoriatic arthritis, gout, ankylosing spondylitis, and other inflammatory diseases contribute additional treatment demand. 

Retail Pharmacy: Retail pharmacies provide broad access to rheumatology medicines and are particularly important for conventional prescription drugs, OTC pain-management products, maintenance therapies, and medicines used for chronic musculoskeletal conditions. The channel benefits from extensive geographic availability, established pharmacist-patient relationships, prescription-refill services, and increasing consumer demand for convenient healthcare access. More than 500 million people globally are affected by osteoarthritis, creating a substantial patient base requiring repeated symptom-management and prescription treatment. In the United States, more than 32 million adults have osteoarthritis, while approximately 1.5 million adults have rheumatoid arthritis. Retail pharmacies therefore serve a large population using analgesics, NSAIDs, corticosteroids, conventional DMARDs, and selected supportive treatments.

Online Pharmacy: Online pharmacies are becoming an increasingly relevant application channel in the Rheumatology Therapeutics Market because patients with chronic musculoskeletal and autoimmune disorders often require recurring medication refills and may experience mobility limitations. Digital pharmacy platforms can support prescription ordering, home delivery, refill reminders, electronic medication records, and remote pharmacist communication. These services are particularly useful for patients with osteoarthritis, rheumatoid arthritis, gout, and other chronic conditions requiring repeated medication access. More than 500 million people worldwide live with osteoarthritis, and the long-term nature of treatment creates a large potential population for digital prescription fulfillment. 

Rheumatology Therapeutics Market Regional Outlook

The Rheumatology Therapeutics Market demonstrates broad geographic demand, supported by the prevalence of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, lupus, and other inflammatory disorders. Based on an indicative global demand allocation, North America accounts for approximately 37% of the market, Europe about 28%, Asia-Pacific approximately 27%, and the Middle East & Africa close to 8%, together representing 100% of the market. North America benefits from high biologic adoption, specialist availability, advanced diagnostics, and strong reimbursement infrastructure. Europe is supported by established rheumatology networks and expanding biosimilar utilization. 

NORTH AMERICA

North America represents the leading regional segment of the Rheumatology Therapeutics Market, with an indicative share of approximately 37% of global market demand. The region's market size is supported by a large diagnosed population, advanced specialty-care infrastructure, high utilization of biologic DMARDs, targeted synthetic DMARDs, conventional DMARDs, corticosteroids, and nonsteroidal anti-inflammatory medicines. In the United States, approximately 1.5 million adults are affected by rheumatoid arthritis, while more than 32 million adults live with osteoarthritis. Women account for roughly 70% of diagnosed rheumatoid arthritis cases in the United States, reinforcing the importance of gender-specific disease awareness and long-term treatment programs. Canada contributes additional demand through established public healthcare and specialty pharmacy systems. Biosimilar adoption is becoming increasingly important, with selected biosimilars capable of producing approximately 15%–40% lower treatment costs compared with reference biologics depending on product and payer conditions. North America's market share is also strengthened by high prescription-drug penetration, advanced clinical trials, specialist rheumatologist networks, and strong pharmaceutical R&D capabilities. Hospital and specialty pharmacies remain important channels for complex biologics, while retail and online pharmacies support maintenance medicines and OTC products. 

EUROPE

Europe accounts for an indicative 28% share of the global Rheumatology Therapeutics Market, making it the second-largest regional market based on treatment demand and pharmaceutical utilization. The European market size is supported by broad healthcare coverage, established rheumatology centers, structured treatment guidelines, increasing biosimilar penetration, and a large population requiring chronic management of autoimmune and musculoskeletal disorders. Rheumatoid arthritis affects approximately 0.5%–1% of adults in many populations, while osteoarthritis creates an even larger treatment pool. European countries have progressively increased the use of biosimilars for mature biologic therapies, and competitive products can generate treatment-cost reductions of approximately 15%–40% in selected categories. Germany, the United Kingdom, France, Italy, and Spain represent major contributors to regional demand. European treatment strategies increasingly emphasize early diagnosis, treat-to-target approaches, disease remission, patient monitoring, and appropriate switching between biologic or targeted therapies. The region has substantial demand for TNF inhibitors, interleukin inhibitors, JAK inhibitors, conventional DMARDs, corticosteroids, and symptomatic treatments. 

GERMANY Rheumatology Therapeutics Market

Germany represents one of Europe's most important national markets for rheumatology therapeutics, with an indicative share of approximately 8% of global demand and around 28% of the European regional segment. The German market benefits from extensive statutory health insurance coverage, specialist rheumatology services, hospital infrastructure, and established pharmaceutical distribution networks. Rheumatoid arthritis and osteoarthritis generate significant treatment requirements, while psoriatic arthritis, gout, ankylosing spondylitis, and systemic autoimmune diseases add demand for specialty medicines. Conventional DMARDs remain important for initial management, while biologics and targeted synthetic therapies are widely relevant for patients with inadequate response to conventional treatment. Biosimilar competition has become an important procurement factor, with selected categories capable of producing approximately 15%–40% reductions in treatment costs. German physicians increasingly emphasize early disease control, remission, and monitoring of inflammatory activity. Hospital pharmacies and specialist practices are important channels for advanced therapies, while retail pharmacies support maintenance treatment and OTC symptom management. 

UNITED KINGDOM Rheumatology Therapeutics Market

The United Kingdom accounts for an indicative 5% of global Rheumatology Therapeutics Market demand and approximately 18% of the European market. The UK market is supported by a centralized healthcare structure, specialist rheumatology services, clinical treatment pathways, and growing use of biosimilars. Rheumatoid arthritis affects hundreds of thousands of people in the country, while osteoarthritis affects millions and represents a major source of chronic pain and disability. Prescription treatment includes conventional DMARDs, biologics, targeted synthetic therapies, corticosteroids, and symptomatic medicines. Biosimilars have gained importance in UK procurement because competition can deliver approximately 15%–40% treatment-cost reductions in selected biologic categories. National treatment protocols emphasize early diagnosis, disease control, patient monitoring, and cost-effective medicine selection. Hospital and specialist pharmacy channels remain critical for biologic and advanced therapies, whereas community pharmacies support prescription maintenance medicines and OTC pain-management products. Digital healthcare and remote consultations are also improving treatment monitoring and prescription continuity. 

ASIA-PACIFIC

Asia-Pacific represents an indicative 27% share of the global Rheumatology Therapeutics Market, making it one of the most important growth-oriented regions in terms of patient population and expanding treatment access. The regional market size is supported by large populations in China, Japan, India, South Korea, Australia, and Southeast Asia, where diagnosis and specialist treatment availability are progressively improving. Rheumatoid arthritis affects approximately 0.5%–1% of adults globally, while osteoarthritis affects more than 500 million people worldwide, creating significant potential demand across Asia-Pacific. Japan has a mature specialty pharmaceutical environment, China has rapidly expanding domestic pharmaceutical capabilities, and India provides a large generic medicine manufacturing base. Biosimilars and conventional DMARDs are particularly important for improving affordability, while biologics and targeted synthetic therapies are gaining broader use in advanced healthcare systems. Urbanization, aging populations, rising healthcare expenditure, increased awareness of autoimmune diseases, and expansion of specialist hospitals are supporting treatment adoption. However, substantial differences in reimbursement, diagnosis rates, medicine availability, and healthcare infrastructure remain across individual countries. 

JAPAN Rheumatology Therapeutics Market

Japan represents an indicative 7% share of global Rheumatology Therapeutics Market demand and approximately 26% of the Asia-Pacific regional market. The country has a mature pharmaceutical sector, high healthcare coverage, strong specialist infrastructure, and a substantial aging population. Rheumatoid arthritis is a major focus of specialty treatment, while osteoarthritis and other degenerative joint disorders create additional demand for pain-management and anti-inflammatory therapies. Japan has broad availability of conventional DMARDs and advanced biologic treatments, including therapies targeting TNF, interleukin pathways, B cells, and other immune mechanisms. The aging population increases the importance of treatment strategies that balance efficacy, safety, comorbidities, and medication burden. Japanese healthcare providers increasingly emphasize early treatment and disease control to reduce functional impairment. Hospital pharmacies and specialist clinics are important for advanced medicines, while retail pharmacies support conventional prescriptions and OTC products. Biosimilar utilization offers opportunities for healthcare cost optimization, particularly in mature biologic categories. 

CHINA Rheumatology Therapeutics Market

China represents an indicative 9% share of the global Rheumatology Therapeutics Market and approximately 33% of Asia-Pacific demand. Its market size is supported by a very large population, increasing diagnosis of autoimmune and inflammatory diseases, expanding hospital infrastructure, growing pharmaceutical manufacturing capacity, and increasing availability of domestic biologics and biosimilars. Rheumatoid arthritis, osteoarthritis, gout, psoriatic arthritis, and lupus contribute to pharmaceutical demand across urban and increasingly developed healthcare settings. Conventional DMARDs remain important because affordability influences treatment selection, while biologic and targeted therapies are gaining adoption among patients with moderate-to-severe disease. National procurement and pricing initiatives can significantly affect medicine utilization and manufacturer strategies. Domestic pharmaceutical companies are increasingly developing biosimilars and innovative biologic therapies, creating greater competition with multinational products. Hospital pharmacies remain the primary channel for complex prescription medicines, while retail pharmacy is expanding for conventional treatments and OTC products. 

MIDDLE EAST & AFRICA

The Middle East & Africa region represents an indicative 8% share of the global Rheumatology Therapeutics Market, with approximately 5% attributable to the Middle East and 3% to Africa within this regional allocation. The regional market size is influenced by increasing awareness of autoimmune disorders, improvements in specialist healthcare, expanding private hospitals, urbanization, and greater access to prescription medicines. Rheumatoid arthritis, osteoarthritis, gout, lupus, and other inflammatory conditions create ongoing treatment requirements. The Middle East generally has stronger access to biologic and targeted therapies than many African markets because of higher healthcare infrastructure investment and greater private-sector participation. Gulf countries are increasingly developing advanced hospital systems and specialty-care centers, supporting adoption of biologic DMARDs and targeted therapies. African markets remain more dependent on conventional DMARDs, generic medicines, corticosteroids, and affordable symptomatic treatments because affordability and specialist availability remain major considerations. 

List of Key Rheumatology Therapeutics Market Companies

• Takeda Pharmaceutical
• Sanofi
• Genentech
• Novartis
• Janssen Biotech
• Amgen
• AbbVie
• Pfizer
• Bristol-Myers Squibb
• Merck
• UCB Biosciences
• Mitsubishi Tanabe Pharma
• Biogen Inc

Top Two Companies with Highest Share

• AbbVie: approximately 12%–15% share of the advanced prescription rheumatology therapeutics segment.
• Amgen: approximately 7%–10% share of the advanced prescription rheumatology therapeutics segment.

Investment Analysis and Opportunities

Investment opportunities in the Rheumatology Therapeutics Market are increasingly concentrated around biologics, biosimilars, targeted synthetic DMARDs, specialty formulations, and therapies designed for patients who do not achieve adequate disease control with first-line treatment. Rheumatoid arthritis affects approximately 0.5%–1% of adults globally, while osteoarthritis affects more than 500 million people, providing a large addressable patient population. Biosimilars represent an especially attractive investment area because selected products can reduce treatment costs by approximately 15%–40%, creating opportunities for manufacturers and healthcare systems to expand treatment access. 

B2B investment opportunities extend across pharmaceutical manufacturing, contract development and manufacturing, specialty distribution, diagnostics, clinical research, and digital healthcare. North America represents approximately 37% of global demand, Europe approximately 28%, and Asia-Pacific approximately 27%, creating three major investment centers with different commercial priorities. North America offers opportunities in advanced biologics and specialty therapies, Europe provides strong potential for biosimilar and cost-efficient treatment models, while Asia-Pacific provides substantial volume opportunities through expanding healthcare access and local manufacturing. Approximately 15%–40% cost reductions associated with selected biosimilars can encourage payer adoption and improve patient access. 

New Products Development

New product development in the Rheumatology Therapeutics Market is increasingly focused on selective immune pathways, improved safety, convenient administration, and differentiated patient outcomes. Biologic therapies targeting TNF, interleukin pathways, B cells, and other inflammatory mechanisms remain important, while JAK inhibitors and other targeted synthetic therapies continue to expand treatment options. Developers are increasingly evaluating oral formulations, extended-release products, self-administered injections, and longer-acting therapies that can reduce treatment burden. Biosimilar development is another major area, with selected biosimilars capable of producing approximately 15%–40% lower treatment costs than reference biologics. 

Product innovation is also moving toward personalized and digitally supported treatment. Biomarker-based patient selection can potentially improve response rates by identifying patients more likely to benefit from particular mechanisms of action. Digital monitoring tools can help track medication adherence, disease activity, pain, mobility, and treatment response. Approximately 30%–50% of patients with chronic conditions may encounter medication-adherence challenges, increasing the importance of products with simpler dosing schedules and patient-support services. New formulations are also being evaluated to improve stability, administration convenience, storage requirements, and patient acceptance. 

Five Recent Developments

• AbbVie: The company continued strengthening its immunology portfolio with emphasis on IL-23 pathway treatment and advanced therapies for inflammatory diseases. Its Skyrizi and Rinvoq franchises expanded their relevance beyond established indications. 
• Amgen: Amgen continued expanding its biosimilar and inflammation portfolio, supporting broader access to biologic treatment. Biosimilar competition can produce approximately 15%–40% reductions in treatment costs in selected categories. 
• Sanofi: Sanofi continued advancing Dupixent-based immunology development across multiple inflammatory diseases, demonstrating the industry's movement toward pathway-specific treatment. Expansion of immune-mediated disease portfolios is increasing opportunities for therapies addressing. 
• Novartis: Novartis continued emphasizing Cosentyx and other immunology assets across inflammatory disease indications. The company's strategy reflects increasing demand for targeted treatment of psoriatic arthritis and related inflammatory conditions. 
• Bristol-Myers Squibb: Bristol-Myers Squibb continued developing its immunology and rheumatology portfolio around targeted treatment approaches. The company's deucravacitinib-based development activities demonstrate the broader industry emphasis on selective immune signaling and oral therapies. 

Report Coverage Of Rheumatology Therapeutics Market

The Rheumatology Therapeutics Market Report covers major therapeutic categories, distribution channels, regional markets, disease areas, competitive positioning, investment opportunities, and product-development trends. The report evaluates Rx Drugs and OTC Drugs and examines applications across Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, lupus, ankylosing spondylitis, and other inflammatory conditions are considered within the broader demand environment. Rheumatoid arthritis affects approximately 0.5%–1% of adults globally. 

Regional coverage includes North America with an indicative 37% share, Europe with approximately 28%, Asia-Pacific with approximately 27%, and Middle East & Africa with approximately 8%, representing 100% of the global market allocation. Country-level analysis includes the United States, Germany, the United Kingdom, Japan, and China, with emphasis on treatment access, pharmaceutical infrastructure, specialist availability, reimbursement, biosimilar adoption, and distribution channels. Competitive coverage includes Takeda Pharmaceutical, Sanofi, Genentech, Novartis, Janssen Biotech, Amgen, AbbVie, Pfizer, Bristol-Myers Squibb, Merck, UCB Biosciences, Mitsubishi Tanabe Pharma, and Biogen Inc.